In this week's video, Dr. Brian Durie answeres the question on how the International Myeloma Foundation contributes to the acceleration of new drug approvals for multiple myeloma.

Bottom Line:

The IMF's work helps expedite the progress of new drugs from trial phase to full approval.

Previous Post
More evidence links toxic chemical exposure to MGUS and myeloma
Next Post
Huge interest in toxic chemicals triggered by last week's blog: follow up notes

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.